Dr. Namandjé N. Bumpus Principal Deputy Commissioner - FDA | Official Website
Dr. Namandjé N. Bumpus Principal Deputy Commissioner - FDA | Official Website
This is a 42.9% decrease from the number of companies cited in the previous year.
Of the nine citations issued, the most common citation was 'Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit have not been adequately established'.
Most of the companies cited were involved in the Devices sector.
All of the companies cited should take voluntary actions to correct their managing operations.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
The FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality, according to its website.
Company Name | Area of Business | Inspection Date | Issue Cited |
---|---|---|---|
EmCyte Corporation | Devices | 11/15/2023 | Documentation |
EmCyte Corporation | Devices | 11/15/2023 | Lack of or inadequate complaint procedures |
KSG Trade Company | Food and Cosmetics | 03/02/2023 | Develop FSVP |
Pro Med Instruments, Inc. | Devices | 02/15/2023 | Whether reporter is an importer |
Pro Med Instruments, Inc. | Devices | 02/15/2023 | Contamination control, Lack of or inadequate procedures |
Pro Med Instruments, Inc. | Devices | 02/15/2023 | Lack of or inadequate complaint procedures |
Pro Med Instruments, Inc. | Devices | 02/15/2023 | Service reports |
Southwest Florida Fertility Center, P. A. | Biologics | 03/08/2023 | Testing, screening, donor eligibility procedures |
Southwest Florida Fertility Center, P. A. | Biologics | 03/08/2023 | Risk factors, clinical evidence |